eli lilly

WuXi & Lilly To Develop Cardiovascular Drug In China

As part of Lilly’s ‘In China, For China’ strategy, the small molecule drug is intended to help the 276 million Chinese patients affected by high cholesterol.

Innovent & Lilly Announce US$456 Million Cancer Drug Deal

Innovent and Lilly form a broad alliance to develop at least three cancer drugs over the next decade.

Lilly & Hanmi Ink US$690 Million Deal

Eli Lilly has acquired Hanmi's BTK inhibitor HM71224, a small molecule soon to enter Phase II trials for autoimmune diseases.

Lilly Expands Partnership With China’s Novast

Building on an earlier 2012 agreement, Lilly intends to invest US$60-70 million in Chinese generics manufacturer Novast.

Eli Lilly Funds US$350 Million To Expand Insulin Production In China

Eli Lilly and Company will invest US$350 million to expand its insulin cartridge manufacturing capacity in China.

Hutchison MediPharma And Eli Lilly Collaborate On Cancer Therapy

Hutchison MediPharma has entered into a collaboration with Eli Lilly to develop fruquintinib, a targeted oncology therapy against solid tumors.

Linagliptin Controlled Type II Diabetes In Asian Clinical Trials

Two phase III clinical studies show that linagliptin improved blood glucose control in Asian adults with type II diabetes.

Eli Lilly’s Elanco Invests US$100m In China Animal Healthcare

Elanco has announced a US$100 million investment to purchase a minority equity stake in China Animal Healthcare Ltd.

Lilly Expands Partnership With Chinese Generics Manufacturer Novast

Eli Lilly and Company announced this month an expanded collaboration with Novast Laboratories to build a portfolio of Lilly branded generic medicines in China.

Eli Lilly Opens Diabetes R&D Center In Shanghai

Eli Lilly has officially opened the Lilly China Research and Development Center which will investigate novel diabetes medicines tailored specifically for the Chinese population.